Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: John Moore/Getty Images

Some liberal lawmakers want to add more punitive action — like fines and heavy industry regulation — to Congress' response to the opioid epidemic.

Between the lines: This congress isn't going to pass anything like the bill that Sen. Bernie Sanders introduced last week. But liberal support for such a measure could grow as the industry players who pushed and profited from opioid sales continue to go undisciplined by Congress.

Where it stands: Congress' work right now is largely focused on curbing the epidemic and treating those addicted.

  • The Energy and Commerce Committee is also investigating drug distributors in West Virginia. Committee chairman Greg Walden has said bad actors should be held accountable, and drug distributor CEOs will testify before the committee next month.
  • Sen. Claire McCaskill is leading an investigation into opioid manufacturers and distributors. She told me this week she'd like to see the results before she comments on whether punitive action should be taken.
  • There are several pending court cases against opioid makers across the country.

Yes, but: Some Democrats – like Sanders – want to go further. He has proposed fines on drug companies that falsely market opioids as nonaddictive; criminal liability for top executives; and a $7.8 billion fine for any company that is found liable for contributing to the opioid epidemic.

Why you'll hear about this again: Cosponsors of the Sanders bill include Kamala Harris and Kristen Gillibrand.

  • But it's not just the presidential hopefuls getting on board. Sen. Ron Wyden last week compared opioid makers to tobacco companies and said that "the executives need to be brought before [Congress] and held accountable."
  • "Congress would be derelict in its responsibilities if it pretends there is no profit motive or corporate scheming behind this addiction crisis," Wyden said.

And the moderates? Sen. Joe Manchin has a bill that would impose a one-cent tax for each milligram of opioids in a pain pill. The funds raised by the tax would then be used for substance abuse treatment. Cosponsors include Democrats across the ideological spectrum, like Amy Klobuchar, Heidi Heitkamp and Elizabeth Warren.

  • "I view it as, the justice system will take care of part of this with lawsuits, but I think the other piece of it is doing something to get money for treatment," Klobuchar told me last week.

Go deeper

Cuomo: "No way I resign" after sexual harassment accusations

Cuomo at a Feb. 24 press conference. Photo: Seth Wenig/pool/AFP via Getty Images

New York Gov. Andrew Cuomo (D) was defiant on Sunday, stating again that he would not resign even as more former aides have come forward with allegations of sexual harassment and inappropriate behavior.

The big picture: Cuomo has denied all sexual harassment allegations against him and said that he "never inappropriately touched anybody." He acknowledged in a statement that "some of the things I have said have been misinterpreted as an unwanted flirtation." Some of the calls for Cuomo to resign have come from within the Democratic party.

N.Y. Times faces culture clashes as business booms

Illustration: Sarah Grillo/Axios

New York Times columnist David Brooks' resignation from a paid gig at a think tank on Saturday is the latest in a flurry of scandals that America's biggest and most successful newspaper company has endured in the past year.

Driving the news: Brooks resigned from the Aspen Institute following a BuzzFeed News investigation that uncovered conflicts of interest between his reporting and money he accepted from corporate donors for a project called "Weave" that he worked on at the nonprofit.

America rebalances its post-Trump news diet

Illustration: Annelise Capossela/Axios

Nearly halfway through President Biden's first 100 days, data shows that Americans are learning to wean themselves off of news — and especially politics.

Why it matters: The departure of former President Trump's once-ubiquitous presence in the news cycle has reoriented the country's attention.